AbbVie Phase 2 eczema drug meets primary endpoint in trial

September 30, 2026 1:30 AM

AbbVie (NYSE: ABBV) announced Phase 2 trial results for zumilokibart, an investigational antibody targeting IL-13, in adults with moderate to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found